The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
SITC 2024 – Arcus springs a TIGIT surprise
Reports of Arc-10's failure are greatly exaggerated, the company argues.
SITC 2024 preview – duelling TIGIT duds
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
Triple meeting 2024 – casdatifan looks like Welireg
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
Triple meeting 2024 – plenary focus
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
